Pulmatrix (PULM) Enterprise Value (2013 - 2026)
Pulmatrix (PULM) posted Enterprise Value of -$4.0 million for Q1 2026, up 1.57% sequentially from -$4.1 million in Q4 2025, and up 47.79% YoY from -$2.7 million in Q1 2025.
Pulmatrix (PULM) Enterprise Value (2013 - 2026) Analysis & Trends
Pulmatrix has reported Enterprise Value for 14 years, with the latest figure at -$4.0 million in Q1 2026.
- Quarterly Enterprise Value rose 47.79% year-over-year to -$4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.0 million (up 47.79% YoY) and the FY2025 annual result came in at -$4.1 million, up 57.06% from the prior year.
- Enterprise Value climbed to -$4.0 million in Q1 2026 per PULM's latest filing, from -$4.1 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$4.0 million in Q1 2026 and troughed at -$47.5 million in Q1 2022.
- A 5-year average of -$20.1 million and a median of -$16.3 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value gained 23.66% in 2022, then surged 57.79% in 2025.
- Over 5 years, Enterprise Value stood at -$35.8 million in 2022, then soared by 46.42% to -$19.2 million in 2023, then surged by 50.34% to -$9.5 million in 2024, then soared by 57.06% to -$4.1 million in 2025, then advanced by 1.57% to -$4.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$4.0 million, -$4.1 million, and -$4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 2.12 Bn |
| 10 | Pulmatrix | 5.55 Mn | 5.55 Mn | - | -2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.90 Mn |
| Mar 31, 2026 | -4.02 Mn |
| Dec 31, 2025 | -4.09 Mn |
| Sep 30, 2025 | -4.79 Mn |
| Jun 30, 2025 | -5.83 Mn |
| Mar 31, 2025 | -7.71 Mn |
| Dec 31, 2024 | -9.52 Mn |
| Sep 30, 2024 | -10.78 Mn |
| Jun 30, 2024 | -13.80 Mn |
| Mar 31, 2024 | -16.30 Mn |
| Dec 31, 2023 | -19.17 Mn |
| Sep 30, 2023 | -21.49 Mn |
| Jun 30, 2023 | -25.94 Mn |
| Mar 31, 2023 | -30.91 Mn |
| Dec 31, 2022 | -35.78 Mn |
| Sep 30, 2022 | -40.84 Mn |
| Jun 30, 2022 | -43.06 Mn |
| Mar 31, 2022 | -47.53 Mn |
| Dec 31, 2021 | -53.84 Mn |
| Sep 30, 2021 | -53.49 Mn |